Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462667 | 0.86 | GAA (0.61) | GAARAB9ANPC1NPSR1ADORA3 | |
| SCHEMBL5465546 | 0.84 | GAA (0.69) | GAARAB9ANPC1NPSR1ADORA3 | |
| SCHEMBL5467334 | 0.83 | NPSR1 (0.64) | GAARAB9ANPC1NPSR1ADORA3 | |
| SCHEMBL5478064 | 0.79 | KMT2A (0.52) | GAARAB9ANPC1ADORA3LMNA | |
| SCHEMBL5465532 | 0.79 | ADORA3 (0.65) | GAARAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL5468779 | 0.79 | ADORA3 (0.65) | GAARAB9ANPC1NPSR1ADORA3 | |
| SCHEMBL5467323 | 0.78 | GAA (0.60) | GAARAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL5473336 | 0.77 | GAA (0.59) | GAANPSR1ADORA3ADORA2ALMNA | |
| SCHEMBL5479318 | 0.75 | GAA (0.56) | GAANPSR1ADORA3ADORA2ALMNA | |
| SCHEMBL5465150 | 0.74 | HDAC1 (0.58) | GAARAB9ANPC1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099938-A1 | Antistress drug and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1679309-A1 | ANTISTRESS DRUG AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099938-A1 | Antistress drug and medical use thereof | NPSR1, MC2R, SRR | GAA 3044/4885RAB9A 3039/4885NPC1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.